Merit Medical Systems has concluded the acquisition of a dialysis catheter product portfolio and the BioSentry Tract Sealant System Biopsy product from AngioDynamics for a cash consideration of $100m.

Under the deal, Merit Medical purchased DuraMax, DuraFlow, Trio-CT, Evenmore Schon X and Vaxel Plus haemodialysis catheter brands from AngioDynamics.

The BioSentrybiopsy tract sealant system helps reduce the incidence of biopsy-related pneumothorax (collapsed lung).

The combined portfolio of products generated sales of approximately $32m for AngioDynamics during the fiscal year 2023.

Proceeds from the transaction will allow AngioDynamics to clear its existing debt and make strategic investments in growth and profitability.

AngioDynamics president and CEO Jim Clemmer said: “This is another significant step in our transformation and finding an excellent partner to take on these leading dialysis and biopsy assets allows our team to more tightly align around the company’s core strategic platforms.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Recently, Merit Medical also purchased the Surfacer Inside-Out access catheter system from Bluegrass Vascular Technologies for $32.5m in cash.

The Surfacer is a unique device developed to facilitate repeated right-sided catheter placement for central venous access in patients with venous obstructions.

Merit chairman and CEO Fred Lampropoulos said: “These acquisitions strengthen our position in the dialysis and biopsy markets and expand the foundation of our growing speciality dialysis device offering, which includes WRAPSODY Cell-Impermeable Endoprosthesis, HeROGraft and the Surfacer System devices.

“Many dialysis patients rely on these solutions to receive vital therapies. Combining this broad portfolio of interventional solutions within Merit will allow us to leverage our physician relationships and commercial infrastructure to serve more patients in the multi-billion dialysis market.”